Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.

A secondary analysis of a real-world cohort with tirzepatide as the direct subject in an older population that trials often underrepresent. Reductions in HbA1c and body weight were associated with treatment, and no severe hypoglycemia was reported, though the authors stress that concomitant insulin and sulfonylurea doses were proactively lowered in many patients. As an observational study without a control arm, it describes real-world use rather than establishing comparative efficacy.